Extended Data Fig. 1. Generation of VSV-CCHF_G and haploid cells screening.
a, Schematic representation of the methods used to produce the VSV-CCHF_G pseudotype virus in HEK293T cells. b, To validate the functionality of the glycoprotein complex in VSV-CCHF, a sero-neutralization was conducted using a serum from vaccinated person or a control serum. Data represent mean ± SD. n = 4. Two-way ANOVA. *p < 0.05, ****p < 0.001, ns: non significant. n = 3 independent experiments. Exact p-values are available in Source data. c, Scheme of the haploid cell screening system. NGS, Next Generation Sequencing d, Validation of resistant clones obtained in the primary haploid screen with VSV-CCHF_G. Each clone (1-13) was isolated, amplified and assessed for infection with the CCHFV IbAR10200 laboratory strain (MOI 0.1). The data show the level of infection for each clone compared to wild-type haploid cells (AN3-12) as determined by RT-PCR for CCHFV and RNase P RNA 24hpi.